Interestingly, in RAG1 KO mice bearing B16 tumors, the tumor growth inhibition effect of the indicated treatment (monotherapy or combined therapy) was obviously weaker than that of the same treatment in the presence of transferred CTLs in RAG1 KO mice bearing B16-OVA tumors. This evidence concerns the gene RAG1 and neoplasm.